NoGeneST™ Anti-GRIN2A Aptamer, aGRIN2A aptamer

Name: NoGeneST™ Anti-GRIN2A Aptamer, aGRIN2A aptamer
SKU: NRYF-0625-HZ123
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ123]

Aptamer designed to specifically recognize the GluN2A subunit of the NMDA receptor, a key protein in synaptic plasticity and epilepsy.

Target:: GRIN2A

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Relevant Diseases

Schizophrenia

Properties

Size

5 nmol. 10 nmol. 50 nmol

Soluble In

PBS; buffer system with Serum; other

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

GRIN2A

Full Name

Glutamate Receptor Ionotropic, NMDA 2A

Gene ID

2903

Uniprot ID

Q12879

Target Overview

GRIN2A is a gene that encodes the GluN2A subunit of the NMDA (N-methyl-D-aspartate) receptor. NMDA receptors are glutamate-gated ion channels crucial for excitatory neurotransmission in the brain. They are essential for synaptic plasticity, a fundamental process that underlies learning and memory. The specific subunit composition of the NMDA receptor, including the presence of GluN2A, dictates its functional properties, such as its gating kinetics and pharmacology. Mutations in the GRIN2A gene are a significant cause of a spectrum of neurodevelopmental disorders, including epilepsy with speech impairment and intellectual disability.

Publications